OX40 signaling can enhance T cell differentiation and survival via effects on IL-2 and IL-7-mediated signaling, and via increasing the anti-apoptotic molecules Bcl-2 and Bcl-xL (130) Essentially, providing OX40 triggering augmented anti-tumor activity in a preclinical model of adoptive T cell transfer mediated by both CD4+ and CD8+ T cells (131). The gene discussed is TNFRSF4; the disease is neoplasm.